Physician profile
Marie Easterlin
NPI 1003008111
$2,400.71
in general payments reported to CMS, 2019-2025
24 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $194 · 2021: $383 · 2022: $379 · 2023: $299 · 2024: $465 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $529.76 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $257.38 | 2022-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $228.09 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $223.66 | 2021-2025 | |
| Pfizer INC. | $207.62 | 2019-2025 | |
| Millicent US INC | $127.16 | 2021-2025 | Intrarosa, Femring, Femlyv |
| Agile Therapeutics, INC. | $90.65 | 2022-2024 | Twirla |
| Hologic Sales and Service, LLC | $85.79 | 2019-2024 | Aptima, Thinprep 2000 Processor, Novasure |
| Lilly USA, LLC | $75.89 | 2025 | Zepbound, Mounjaro |
| Biohaven Pharmaceutical Holding Company Ltd. | $75.60 | 2022 | |
| Novo Nordisk INC | $65.85 | 2022-2024 | Wegovy |
| Sumitomo Pharma America, INC. | $63.40 | 2023-2025 | Myfembree |
| Exact Sciences Corporation | $62.94 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $62.49 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.30 | 2019-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.79 | 2020-2021 | |
| Amgen INC. | $26.82 | 2019 | |
| Avion Pharmaceuticals | $25.76 | 2019-2022 | |
| Scynexis, INC. | $23.53 | 2022 | |
| Aspira Women'S Health INC | $19.63 | 2024 | Ova1 |
| Covidien Lp | $17.33 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.67 | 2019 | |
| Coopersurgical, INC. | $13.35 | 2019 | |
| Exeltis, USA INC. | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Easterlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.